Litigation Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2020)
✉ Email this page to a colleague
United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2020)
| Docket | ⤷ Start Trial | Date Filed | 2020-06-04 |
| Court | District Court, D. Delaware | Date Terminated | 2022-09-09 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | Jennifer L. Hall |
| Parties | LIQUIDIA TECHNOLOGIES, INC. | ||
| Patents | 10,376,525; 10,716,793; 10,898,494; 11,826,327; 6,521,212; 6,756,033; 6,765,117; 7,417,070; 7,544,713; 7,999,007; 8,114,021; 8,497,393; 9,108,015; 9,339,507; 9,358,240; 9,593,066; 9,604,901 | ||
| Attorneys | William C. Jackson | ||
| Firms | Shaw Keller LLP, DE | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in United Therapeutics Corporation v. Liquidia Technologies, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-06-04 | External link to document | |||
| 2020-06-04 | 108 | Redacted Document | the validity of patents related to the Patents-in-Suit, such as U.S. Patent Nos. 8,497,393 (“the ’393…concerning [U.S. Patent No. 8,497,393] in association with the ’901 and ’066 patents,” asserting that…concerning the Related Patents and Applications, including U.S. Patent Nos. 8,497,393; 9,339,507; 9,358,…PTAB's 4 The '393 patent is U.S. Patent No. 8,497,393. Case 1:20-cv-00755-RGA-JLH Document…Hatch‐Waxman litigation involving the Patents‐in‐Suit and U.S. Patent Nos. 8,497,393; 9,339,507; and 9,358,240, | External link to document |
| 2020-06-04 | 109 | Ex. 1 - Second Amended Complaint | seq., involving United States Patent Nos. 9,593,066 (“the ’066 patent”) (attached as Exhibit A hereto…the expiration of the ’066 patent, the ’901 patent, and the ’793 patent, to manufacture, market, and… more claims of the ’066 patent, the ’901 patent, and the ’793 patent, which have been listed in …Liquidia has infringed the ’066 patent, the ’901 patent, and the ’793 patent; and …or more of the ’066 patent, the ’901 patent, and the ’793 patent, prior to the expiration | External link to document |
| 2020-06-04 | 11 | Answer to Complaint AND Counterclaim | UTC’s U.S. Patent No. 8,497,393, finding that the product claimed in the ʼ393 patent was not novel … UTC’s U.S. Patent No. 8,497,393, finding that the product claimed in the ʼ393 patent was not novel …assert a patent infringement action. Liquidia admits that U.S. Patent No. 9,593,066 (the “’066 patent”) and… and U.S. Patent No. 9,604,901 (the “’901 patent”) (collectively the “patents-in-suit”) each bear the…the ’066 patent is a product-by-process patent, and that the product claimed in the ’066 patent is novel | External link to document |
| 2020-06-04 | 117 | Proposed Order | claims of U.S. Patent Nos. 8,593,066 (the “’066 patent”) and 9,604,901 (the “’901 patent”), the terms…range of 15°C to 30°C) ’066 patent, claims 6 and 8; ’901 patent, claim 6 “stored” / “storing…and ordinary meaning ’066 patent, claims 6 and 8; ’901 patent, claim 6 1 The Court… plain and ordinary meaning ’066 patent, claims 1 and 8 “ambient temperature” …treprostinil,” appearing in claims 1 and 8 of the ʼ901 patent, but will issue its order regarding these terms | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
